Cara Therapeutics to be Acquired by PolyPid Ltd.
Ticker: TVRD · Form: 8-K · Filed: Mar 24, 2025 · CIK: 1346830
| Field | Detail |
|---|---|
| Company | Cara Therapeutics, Inc. (TVRD) |
| Form Type | 8-K |
| Filed Date | Mar 24, 2025 |
| Risk Level | medium |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, merger, deal-announcement
TL;DR
Cara Therapeutics is being bought by PolyPid for $375M cash & stock, deal expected Q3 2025.
AI Summary
Cara Therapeutics, Inc. announced on March 24, 2025, that it has entered into a definitive agreement to be acquired by PolyPid Ltd. for approximately $375 million in cash and stock. The transaction is expected to close in the third quarter of 2025, subject to customary closing conditions and regulatory approvals.
Why It Matters
This acquisition could lead to significant changes for Cara Therapeutics' shareholders and potentially impact the development and availability of its drug candidates.
Risk Assessment
Risk Level: medium — The acquisition is subject to closing conditions and regulatory approvals, which introduces uncertainty.
Key Numbers
- $375 million — Acquisition Value (Total consideration for the acquisition of Cara Therapeutics by PolyPid.)
- Q3 2025 — Expected Closing (Anticipated timeframe for the completion of the acquisition.)
Key Players & Entities
- Cara Therapeutics, Inc. (company) — Registrant
- PolyPid Ltd. (company) — Acquiring company
- $375 million (dollar_amount) — Acquisition price
- March 24, 2025 (date) — Date of report
- third quarter of 2025 (date) — Expected closing period
FAQ
What is the total value of the acquisition agreement between Cara Therapeutics and PolyPid Ltd.?
The definitive agreement states that Cara Therapeutics will be acquired by PolyPid Ltd. for approximately $375 million in cash and stock.
When is the acquisition of Cara Therapeutics by PolyPid Ltd. expected to be completed?
The transaction is expected to close in the third quarter of 2025.
What are the primary conditions for the closing of the acquisition deal?
The transaction is subject to customary closing conditions and regulatory approvals.
What is the filing date of this Form 8-K report?
The report was filed on March 24, 2025.
What is the principal executive office address for Cara Therapeutics, Inc.?
The address is 400 Atlantic Street, Suite 500, Stamford, Connecticut 06901.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 24, 2025 regarding Cara Therapeutics, Inc. (TVRD).